Business Wire

MA-ROCKET-SOFTWARE

1.5.2024 16:06:35 CEST | Business Wire | Press release

Share
Rocket Software Closes $2.275B Acquisition of OpenText’s Application Modernization and Connectivity Business

Rocket Software, Inc. (“Rocket Software”), a global technology leader in modernization software, has expanded upon its position as a partner of choice empowering the world's leading businesses on their modernization journeys. Closing the acquisition of the Application Modernization and Connectivity (AMC) business of OpenText, formerly part of Micro Focus, Rocket Software now offers customers modernization software solutions spanning the mainframe to the cloud. With a total purchase price of $2.275 billion, before taxes, fees and other adjustments, the deal increases the company’s revenue by over 60% and expands its customer base to more than 12,500 companies and network to more than 750 partners worldwide. In addition, the company welcomes more than 770 new software engineers, go-to-market professionals and other supporting team members and is hiring hundreds of additional Rocketeers to complement its existing team.

“Rocket Software’s customers are global market leaders that are constantly setting new benchmarks for excellence and innovation in their industries that we are proud to power and advance,” said Milan Shetti, president and CEO of Rocket Software. “The acquisition of the OpenText AMC business is a significant milestone that sets a similar new standard for modernization innovation and excellence at Rocket Software and greatly accelerates our strategic growth and market penetration. We now have the solutions, resources and expertise to tackle modernization challenges at scale, and the continued flexibility, winning culture, proven partnerships and growth mindset necessary to help our customers win today and well into the future.”

“The combination of OpenText’s AMC business and Rocket Software’s highly complementary businesses will create one of the world’s largest mainframe modernization and connectivity software companies,” said Peter Rutten, Research Vice-President, Performance Intensive Computing, IDC. “While many in the industry would champion moving everything to the cloud, or never moving anything off the mainframe, this investment shows Rocket Software’s commitment to meeting clients wherever they are in their modernization journey. Now Rocket Software will have a comprehensive portfolio that allows clients to modernize their workloads in place, move applications to the cloud or a combination of both through a hybrid strategy, which we see most enterprises prefer.”

With the added talent and innovation acquired from AMC, the company has set a new bar for modernization innovation in a single partner that:

  • Offers Leading Technology for Mainframe Modernization by building on its deep expertise and long-standing commitment to optimizing mainframe environments to facilitate seamless, secure and compliant solutions that meet the demands of the digital era
  • Meets Customers Wherever They Are on Their Journeys with an unyielding grasp of the entire landscape and comprehensive range of software solutions for any stage of modernization
  • Values and Builds on Past and Current Investments by recognizing there is a better approach to the ‘rip and replace’ playbook for modernization and instead helps customers leverage their existing foundation for a seamless technological evolution
  • Delivers Solutions as a True Partner, Not Just a Vendor with a 93.7% customer satisfaction rate for enterprises that demand nothing short of excellence, and need a trusted partner

Rocket Software will integrate and continue to develop AMC products to enhance its portfolio, helping customers stay competitive and leverage their data, applications and infrastructure regardless of their modernization strategy. In addition to several complementary Host Connectivity, Application Development and CORBA solutions, Rocket Software will also offer COBOL and Enterprise Suite, market leading technologies that allow companies the ability to run COBOL and PL/I applications on distributed or cloud servers. These added capabilities expand the mainframe modernization approaches that Rocket Software can deliver, enabling choice and allowing customers to run workloads wherever it makes sense for their business. This breadth, and the ability to integrate the various approaches, allows customers to seamlessly connect any combination of solutions across the modernization continuum.

“Application modernization is key to digital transformation in financial services,” said Martin Wildberger, EVP, Innovation & Technology, RBC. “As a Rocket Software customer, we've experienced firsthand the company’s commitment to innovation.”

“Within our organization, the need for modernization is a dynamic process, continually evolving as we grow and scale our business.," said José Fortemps, CTO, AG Insurance. "The OpenText AMC solutions have served us well and, now as part of Rocket Software, we look forward to exploring new opportunities for our data, application and infrastructure that propels us into the future.”

To learn more about Rocket Software and its enhanced capabilities and solutions, click here.

About Rocket Software

Rocket Software is the global technology leader in modernization and partner of choice that empowers the world's leading businesses on their modernization journeys, spanning core systems to the cloud. Trusted by over 12,500 customers and 750 partners, and with more than 3,000 global employees, Rocket Software enables customers to maximize their data, applications, and infrastructure to deliver critical services that power our modern world. Rocket Software is a privately held U.S. corporation headquartered in the Boston area with centers of excellence strategically located throughout North America, Europe, Asia and Australia. Rocket Software is a portfolio company of Bain Capital Private Equity. Follow Rocket Software on LinkedIn and Twitter or visit www.RocketSoftware.com.

Cautionary Information Regarding Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements about our future performance, results and operations following the acquisition of the AMC business. These forward-looking statements are generally identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. These forward-looking statements reflect our views with respect to future events as of the date of this press release and are based on our current expectations, estimates, forecasts, projections, assumptions, beliefs and information. Although management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. All such forward-looking statements are subject to risks and uncertainties, many of which are outside of our control, and could cause future events or results to be materially different from those stated or implied in this press release. Such factors and risks include, but are not limited to, risks related to our ability to successfully integrate the AMC business and realize the expected synergies and certain other risks. It is not possible to predict or identify all such risks. We expressly disclaim any obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430605619/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye